Popularity of the computer science major has more than doubled in the last decade. But with companies like Amazon and Alphabet cutting jobs in favor of AI tools, the computer science market has seen ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Mikeie Reiland is a staff writer for Education at Forbes Advisor. Before coming to Forbes Advisor, he wrote magazine journalism for publications like the Oxford American, Bitter Southerner, and Gravy.

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Abstract: We observe that the computational inefficiency of branched recursive functions was not appropriately covered in almost all textbooks for computer science courses in the first three years of ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...

With AI at the forefront of technology, it is essential to recognize its role in every aspect of our daily operations, from maintaining contact with our customers to leveraging our marketing and human ...

Recursion Pharmaceuticals, Inc., the Salt Lake City based AI-driven drug developer, has agreed to combine businesses with Exscientia plc, a former rival, based in the UK. Neither company has delivered ...